Monoclonal antibodies that block ligand binding to the CD22 rece

Details Monoclonal antibodies that block ligand binding to the CD22 rece Monoclonal antibodies that block ligand binding to the CD22 rece

1993-05-21

1996-01-16

Parr, Margaret

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

5303873, 53038815, 435 7021, 4351722, 43524027, A61K 39395, C07K 1618, C07K 1628, C12N 512

Patent

active

054848920

ABSTRACT:
The present invention is concerned with a series of novel monoclonal antibodies directed against CD22, a B lineage-restricted member of the Ig-superfamily which serves as an adhesion receptor expressed by mature B lymphocytes and is believed to function in the regulation of B cell activation. The monoclonal antibodies (mAb) specifically block red blood cell and leukocyte adhesion (80-100%) to COS cells transfected with CD22 cDNA and also identify a region of CD22 distinct from those defined by previously described CD22 mAb. The invention also encompasses therapeutic compositions including therapeutically effective amounts of a polypeptide comprising the CD22 ligand or portion thereof or of a polypeptide comprising the first two amino terminal Ig-like domains of CD22, or the ligand binding portion thereof. The antibodies and polypeptides of the invention find use in therapeutic methods for treatment of humans to retard or block CD22 adhesive function, particularly in autoimmune disease.

REFERENCES:
Harris et al. Tibtech 11: 42-45 (1993).
Edgington et al. Biotechnology 10: 383-389 (1993).
Clark et al. Ann. Rev. Immunol. 9: 97-127 (1991).
Engel et al. J. Immunol. 150: 4719-4732 (1993).
Aruffo et al., "CD22-mediated stimulation of T cells regulates T-cell receptor/CD3-induced signaling," Immunology 89: 10242-10246 (1992).
Bast et al., "The HB-6, CDw75, and CD76 Differentiation Antigens are Unique Cell-Surface Carbohydrate Determinants Generated by the .beta.-Galactoside .alpha.2,6-Sialyltransferase," J. Cell Biol. 116:423 (1992).
Boue et al., "Structural Characterization of the Human B Lymphocyte-Restricted Differentiation Antigen CD22," J. Immunol. 140(1):192-199 (1988).
Cepko et al., "Construction and Applications of a Highly Transmissible Murine Retrovirus Shuttle Vector," Cell. 37:1053-1062 (1984).
Dorken et al., "Expression of cytoplasmic CD22 in B-cell ontogeny. Leukocyte Typing III. White Cell Differentiation Antigens" McMichael, A. J., Oxford University Press. Oxford 474 (1987).
Dorken et al., "HD39 (B3), A B Lineage-Restricted Antigen Whose Cell Surface Expression is Limited to Resting and Activated Human B Lymphocytes," J. Immunol. 136:4470-4479 (1986).
Ling et al., "B-cell and plasma antigens: new and previously defined clusters" In Leukocyte Typing III. White Cell Differentiation Antigens, McMichael, A. J. Oxford University Press. Oxford pp. 302-335 (1987).
Mason et al., "Value of Monoclonal Anti-CD22 (p135) Antibodies for the Detection of Normal and Neoplastic B Lymphoid Cells," Blood 69:836-840 (1987).
Pezzutto et al., "Amplification of Human B Cell Activation by a Monoclonal Antibody to the B Cell-Specific Antigen CD22, Bp 130/140," J. Immunol. 138: 98-103 (1987).
Pezzutto et al., "Role of the CD22 Human B Cell Antigen in B Cell Triggering by Anti-Immunoglobulin," J. Immunol. 140:1791-1795 (1988).
Powell et al., "Natural Ligands of the B Cell Adhesion Molecule CD22.beta. Carry N-Linked Oligosaccharides with .alpha.=2,6-Linked Sialic Acids That Are Required for Recognition," J. Biol. Chem. 268:(10)7019-7027 (1993).
Schwarting et al., "The Monoclonal Antibodies .alpha.S-HCL 1 (.alpha.Leu-14) and .alpha.S-HCL 3 (.alpha.Leu-M5) Allow the Diagnosis of Hairy Cell Leukemia," Blood 65(4):974-983 (1985).
Schwartz-Albiez et al., "B5.2 The carbohydrate moiety of the CD22 antigen can be modulated by inhibitors of the glycosylation pathway," B-cell antigens-papers, 65-67.
Sgroi et al., "CD22, a B Cell-specific Immunoglobulin Superfamily Member, Is a Sialic Acid-binding Lectin," J. Biol. Chem. 268(10):7011-7018 (1993).
Shawler et al., "Human Immune Response to Multiple Injections of Murine Monoclonal IgG," Immunol. 135(2):1530-1535 (1985).
Stamenkovic et al., "The B Lymphocyte Adhesion Molecule CD22 Interacts with Leukocyte Common Antigen CD45RO on T Cells and .alpha.2-6 Sialyltransferase, CD75, on B Cells," Cell 66:1133-1144 (1991).
Stamenkovic et al., "CD22 Binds to .alpha.-2,6-Sialyltransferase-Dependent Epitopes on COS Cells," Cell 68:1003-1004 (1992).
Stamenkovic et al., "The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion," Nature 345:74-77 (1990).
Wilson et al., "cDNA Cloning of the B Cell Membrane Protein CD22: A Mediator of B--B Cell Interactions," J. Exp. Med. 173:137-146 (1991).

Affiliated with

Also associated with

Rating

Monoclonal antibodies that block ligand binding to the CD22 rece does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal antibodies that block ligand binding to the CD22 rece, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies that block ligand binding to the CD22 rece will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-310378